NCT06992739 2026-04-14
PROTECT-2
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05874401 2025-09-04
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Pharmacosmos A/S
Phase 4 Recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting